When was Acuitas Therapeutic founded?

Acuitas Therapeutic was founded in 2009.

Where is Acuitas Therapeutic located?

Acuitas Therapeutic is headquartered in Vancouver, Canada.

Who is the current CEO of Acuitas Therapeutic?

Tom Madden of Acuitas Therapeutic.

How many employees does Acuitas Therapeutic have?

As of Jun 30, 2026, the latest employee count at Acuitas Therapeutic is 77.

Is Acuitas Therapeutic a funded company?

Acuitas Therapeutic is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Acuitas Therapeutic rank among its competitors?

Acuitas Therapeutic ranks 43rd amongst 348 active competitors, of which 105 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was SonoThera, which secured $125M in Jun, 2026.

Who are the top competitors of Acuitas Therapeutic?

Acuitas Therapeutic's top competitors include Liquidia, Genedit and Aera. Among them, SonoThera secured the most recent funding round in June, 2026.

Acuitas Therapeutic - 2026 Company Profile, Team & Competitors

Company Details

Acuitas Therapeutics (formerly AlCana Technologies) is focussed on developing lipid nanoparticle delivery systems for the intracellular delivery of molecular therapeutics primarily nucleic acids. The system claims to have applications in the protein replacement (mRNA/plasmid delivery) and protein knockdown therapeutics (antisense). Its system comprises of radiolabeled and stable isotope cationic/PEG-lipids. It has partnered with Alnylam Pharmaceuticals, Moderna Therapeutics, the University of British Columbia and IRAP for the systemic delivery of nucleic acid therapeutics.

Website: acuitastx.com
Social
Email ID: *****@acuitastx.com

Key Metrics

Founded Year

2009

Location

Vancouver, Canada

Stage

Unfunded

Ranked

43^rd among 348 active competitors

Employee Count

77 as on Jun 30, 2026

Similar Companies

Liquidia & 458 more

View Acuitas Therapeutic's full profile

Acuitas Therapeutic has not raised any funding rounds yet.

The founders of Acuitas Therapeutic is Tom Madden.

Here are the details of Acuitas Therapeutic's key team members:

Tom Madden: Founder, President & CEO of Acuitas Therapeutic.
Contact Info: 1 email address

View details of Acuitas Therapeutic's Founder profiles and Board Members

Acuitas Therapeutic's employee count trend

Acuitas Therapeutic has 77 employees as of Jun 26. Here is Acuitas Therapeutic's employee count trend over the years:

Employee count trend for Acuitas Therapeutic

Uncover Acuitas Therapeutic's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Acuitas Therapeutic include Liquidia, Genedit and Aera. Here is the list of Top 10 competitors of Acuitas Therapeutic, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Liquidia 2004, Morrisville (United States), Public	Developer of therapeutics for pulmonary hypertension and cardiopulmonary conditions	$90.3M	Morningside, Gates & 18 others	67/100
2nd	Genedit 2016, Berkeley (United States), Series B	Developer of drug delivery system for genetic medicines	$93.5M	IMM Investment, SK & 20 others	65/100
3rd	Aera 2021, Boston (United States), Series B	Developer of genetic medicines across a wide range of therapeutic areas	$193M	Google Ventures, Arch Venture Partners & 3 others	62/100
4th	NanoSyrinx 2018, Coventry (United Kingdom), Series A	Developer of targeted intracellular delivery platform for biological molecules	$21.6M	M Ventures, Octopus Ventures & 15 others	61/100
5th	LogicBio 2013, Lexington (United States), Acquired	Developer of viral vectors for the treatment of genetic and infectious diseases	$49M	Arix Bioscience, Andera Partners & 6 others	61/100
6th	Portal 2023, Watertown (United States), Seed	Provider of cell engineering and cell analytics across research and clinical applications	$25.7M	Pear VC, NFX & 7 others	60/100
7th	Helex 2021, New York City (United States), Seed	Provider of next-generation gene-editing therapies	$6M	pi Ventures, IndieBio & 2 others	59/100
8th	NanoViricides 2005, West Haven (United States), Public	Targeted antiviral therapeutics	-	-	59/100
9th	Genenta Science 2014, Milan (Italy), Public	Developer of lentivirus-based gene and cell therapies for cancer	$33.6M	Mediobanca, Qianzhan & 3 others	58/100
10th	SonoThera 2022, San Francisco (United States), Series B	Developer of nonviral gene therapies for genetic diseases	$186M	Vida Ventures, Arch Venture Partners & 21 others	57/100
43rd	Acuitas Therapeutic 2009, Vancouver (Canada), Unfunded	Lipid nanoparticle delivery systems for nucleic acid therapeutics	-	-	45/100